ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L04

Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis

Maria de la Luz Garcia-Hernandez1, Javier Rangel-Moreno1, Ananta Paine2, Soumyaroop Bhattacharya3, Jeffrey Fox4, Ernest Meyer5, Brian Isett5, Riyue Bao6, Tullia Bruno6 and Christopher Ritchlin7, 1University of Rochester, Rochester, NY, 2ORNA Tx, Southborough, MA, 3Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, 4CMSR, University of Rochester Medical Center, Rochester, NY, 5UPMC Hillman Cancer Center, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA, 7University of Rochester Medical Center, Rochester, NY

Meeting: ACR Convergence 2022

Date of first publication: October 18, 2022

Keywords: Animal Model, autoimmune diseases, Gene Expression, immunology, Late-Breaking 2022, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Late-Breaking Abstracts (L01–L06)

Session Type: Late-Breaking Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: A pivotal clinical characteristic of psoriatic arthritis (PsA) is disease manifestations in several domains (skin, entheses, joints, spine) and multiple domain involvement is prevalent, which complicates therapy. Recent evidence supports a major role for CD8 T cells in the pathogenesis of PsA, however, the role of these cells and serum factors in driving disease in the individual domains is poorly understood. To address this gap, we injected sera and peripheral blood mononuclear cell (PBMC)s from patients with specific phenotypes (psoriasis only, psoriasis and non-erosive arthritis, psoriasis with erosive arthritis, dactylitis) into immunodeficient NSG-SGM3 mice to experimentally evaluate cellular and serum factors that promote domain inflammation in PsA.

Methods: Sera and PBMC were isolated from healthy controls (HC), treatment naïve Psoriasis (Ps) patients with active plaques and PsA. Three groups of NSG-SGM3 mice were intravenously injected with serum and PBMCs collected from healthy (HC), Ps and PsA patients with predominant dactylitis, non-erosive or erosive arthritis. Blood leukocytes, 3-mm skin punch biopsies and synovia (back/front paws) were collected on day 30 post-transfer to quantitate T cells by flow cytometry and immunofluorescence. We examined synovial CD8 T cells with GeoMx digital spatial profiler and next-generation sequencing readout, combined with nSolver software, to define their molecular profiles.

Results: Only NSG-SGM3 injected with serum and PBMCs from PsA patients developed psoriasiform plaques and arthritis (Figure 1). Mice injected with cells and sera from Ps patients showed psoriasiform lesions only. The disease phenotype observed in a patient (predominant dactylitis, erosive or non-erosive arthritis) was also observed in the mouse. Flow cytometry analysis showed an increase of effector memory percentages (hu-Ps; 37.79%, hu-PsA; 22% Vs Ps;16%, PsA 18%) with a decrease in naïve CD8 T cells in the blood of the mice (Ps; 8.91% vs. hu-Ps; 0.48%, hi-PsA; 2.6%). Hu-PsA mice had swollen ankles and developed psoriasiform lesions, dactylitis and pannus infiltration composed of CD8 T cells, macrophages and proliferating CD3 T cells. In contrast, hu-Ps mice had no swollen ankles or dactylitis. All hu-Ps and hu-PsA mice developed skin plaques with increased epidermal thickness (hu-HC 27.6 µm2 vs. hu-PsA 125 µm2, p = 0.025) and numerous proliferating CD3 T cells (hu-HC; 16 cell/ µm2 vs. hu-PsA 204 cells/µm2). GeoMx digital spatial profiler and next-generation sequencing readout showed enrichment of synovial CD8 T cells expressing IL32,GrzK, and GrzA in hu-PsA, but not in hu-HC or hu-Ps. Of note, transfer of serum and PBMCs from a PsA patient showed arthritis and psoriasiform lesion in this model that completely resolved in the patient and murine model following anti-TNF therapy.

Conclusion: These data demonstrate that serum factors and CD8 T cells promote domain specific phenotypes. In addition, this model has potential to provide insight into patient specific therapeutics and underlying disease mechanisms.

Supporting image 1


Disclosures: M. Garcia-Hernandez, None; J. Rangel-Moreno, None; A. Paine, None; S. Bhattacharya, None; J. Fox, None; E. Meyer, None; B. Isett, None; R. Bao, None; T. Bruno, None; C. Ritchlin, AbbVie, Amgen, UCB Pharma, Eli Lilly, Gilead, Janssen, Novartis, Pfizer.

To cite this abstract in AMA style:

Garcia-Hernandez M, Rangel-Moreno J, Paine A, Bhattacharya S, Fox J, Meyer E, Isett B, Bao R, Bruno T, Ritchlin C. Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/psoriatic-arthritis-disease-subtypes-mediated-by-cd8-t-cells-are-phenocopied-in-a-novel-humanized-murine-model-of-psoriasis-and-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/psoriatic-arthritis-disease-subtypes-mediated-by-cd8-t-cells-are-phenocopied-in-a-novel-humanized-murine-model-of-psoriasis-and-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology